Literature DB >> 18455347

Comparison of in-house and commercial 16S rRNA sequencing with high-performance liquid chromatography and genotype AS and CM for identification of nontuberculous mycobacteria.

Peter Daley1, Astrid Petrich, Kevin May, Kathy Luinstra, Candy Rutherford, Pamela Chedore, Frances Jamieson, Marek Smieja.   

Abstract

Sequencing of the 16S gene or other targets and line probe assay are in wide use for the identification of nontuberculous mycobacteria. We compared in-house and commercial sequencing with 3 sequence databases against high-performance liquid chromatography (HPLC) and line probe assay (HAIN Genotype AS and CM) for the identification of 84 reference, clinical, and unique strains representing 41 species. Consensus of methods was used as reference standard. Sequencing identification was more specific and flexible than HPLC, but it was limited by database content and quality as well as fragment length. No one database satisfied all requirements. In-house sequencing was lower in cost than commercial sequencing or line probe assay.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455347     DOI: 10.1016/j.diagmicrobio.2008.02.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Multiplex real-time PCR assay and melting curve analysis for identifying Mycobacterium tuberculosis complex and nontuberculous mycobacteria.

Authors:  Jeong-Uk Kim; Choong-Hwan Cha; Hae-Kyong An
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Culture-negative endocarditis diagnosed using 16S DNA polymerase chain reaction.

Authors:  Stephen Duffett; Bayan Missaghi; Peter Daley
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

3.  Identification of nontuberculous mycobacteria using multilocous sequence analysis of 16S rRNA, hsp65, and rpoB.

Authors:  Si Hyun Kim; Jeong Hwan Shin
Journal:  J Clin Lab Anal       Date:  2017-02-23       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.